Mycapssa FDA Approval History
FDA Approved: Yes (First approved June 26, 2020)
Brand name: Mycapssa
Generic name: octreotide
Dosage form: Delayed-Release Capsules
Company: Chiasma, Inc.
Treatment for: Acromegaly
Mycapssa (octreotide) is an oral formulation of the approved somatostatin analog octreotide for the treatment of acromegaly.
Development Timeline for Mycapssa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.